Scandion Oncology A/S (SCOL) - Total Liabilities
Based on the latest financial reports, Scandion Oncology A/S (SCOL) has total liabilities worth Skr10.01 Million SEK (≈ $1.08 Million USD) as of December 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore SCOL net asset momentum to track the company's year-over-year net asset growth rate.
Scandion Oncology A/S - Total Liabilities Trend (2017–2024)
This chart illustrates how Scandion Oncology A/S's total liabilities have evolved over time, based on quarterly financial data. See SCOL cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Scandion Oncology A/S Competitors by Total Liabilities
The table below lists competitors of Scandion Oncology A/S ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Advanced Info Service Public Company Limited
F:AISF
|
Germany | €312.99 Billion |
|
ECORUB AB B
F:7M8
|
Germany | €38.43 Million |
|
Kiliaro AB
ST:KILI
|
Sweden | Skr15.91 Million |
|
Mind Gym Ltd
LSE:MIND
|
UK | GBX8.86 Million |
|
Ceps PLC
LSE:CEPS
|
UK | GBX19.61 Million |
|
Greiffenberger AG
F:GRF
|
Germany | €31.02 Million |
|
Petros Pharmaceuticals Inc
NASDAQ:PTPI
|
USA | $27.19 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down Scandion Oncology A/S's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Scandion Oncology A/S worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.81 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Scandion Oncology A/S's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Scandion Oncology A/S (2017–2024)
The table below shows the annual total liabilities of Scandion Oncology A/S from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Skr10.01 Million ≈ $1.08 Million |
+191.19% |
| 2023-12-31 | Skr3.44 Million ≈ $369.98K |
-81.98% |
| 2022-12-31 | Skr19.07 Million ≈ $2.05 Million |
+63.33% |
| 2021-12-31 | Skr11.68 Million ≈ $1.26 Million |
-61.77% |
| 2020-12-31 | Skr30.54 Million ≈ $3.29 Million |
+1852.47% |
| 2019-12-31 | Skr1.56 Million ≈ $168.35K |
+57.59% |
| 2018-12-31 | Skr992.64K ≈ $106.82K |
+95.01% |
| 2017-12-31 | Skr509.02K ≈ $54.78K |
-- |
About Scandion Oncology A/S
Scandion Oncology A/S, a clinical-stage biotechnology company, develops medicines for the treatment of cancer. Its lead product candidate is the SCO-101, an oral drug that is in Phase IIa clinical trial for the treatment of drug resistant metastatic colorectal cancer; and in Phase Ib clinical trial for treating unresectable or metastatic pancreatic cancer, as well as in preclinical studies for tr… Read more